Cimarrón Bean Extrudate Solution on Platelet Function and Biochemical Parameters
CBE-SP
Effect of Consuming a Cimarrón Bean Extrudate Solution on Platelet Function and Postprandial Biochemical Parameters
1 other identifier
interventional
30
1 country
1
Brief Summary
This non-randomized acute clinical trial evaluates the effect of consuming a water-based solution of Cimarrón bean extrudate on platelet function and postprandial glycemia in adults. Participants will consume a single 10-gram dose of Cimarrón bean extrudate dissolved in water. Blood samples will be collected before and after the intervention to assess platelet reactivity using flow cytometry and to measure glucose levels through colorimetric spectrophotometry. The total intervention period will last approximately 8 hours. This study aims to explore whether the acute consumption of this legume-based functional product can influence hemostatic and glycemic responses in the postprandial state.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 13, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 19, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 19, 2025
CompletedFirst Submitted
Initial submission to the registry
June 20, 2025
CompletedFirst Posted
Study publicly available on registry
June 29, 2025
CompletedResults Posted
Study results publicly available
April 9, 2026
CompletedApril 9, 2026
December 1, 2025
3 months
June 20, 2025
December 28, 2025
March 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Platelet Reactivity After Acute Consumption of SPVCE
The platelet reactivity was assessed in response to three agonists: ADP, CRP, and TRAP-6. The expression changes of P-selectin and the binding of Fibrinogen to the platelet were measured at baseline (0 hours) and 6 hours. The data were analyzed using dose-response curves and derived metrics of these curves, including basal activity (minimum), maximal response (maximum), EC50, and Capacity of response as the difference between the maximal response and the basal state.
Baseline (0 hours) and 6 hours post-intervention
Secondary Outcomes (3)
Change in Postprandial Blood Glucose Levels After Consumption of SPVCE
Baseline and up to 2 hours post-intervention
Change in Postprandial Plasma Concentration of Total Polyphenols After Consumption of SPVCE
0 minutes (baseline) 2 hour and 6 hours postprandial.
Change in Postprandial Platelet Function (Closure Time) After Consumption of SPVCE
Baseline (0 hours) and 6 hour post-intervention.
Study Arms (1)
SPVCE Intervention
EXPERIMENTALParticipants will receive a single oral dose of 10 grams of SPVCE. Platelet function (Reactivity and blood risk), postprandial glycemia and Polyphenol concentration will be measured before and after the intervention.
Interventions
A single oral dose of 10 grams of Cimarrón bean (Phaseolus vulgaris L., variety Cimarrón) extrudate dissolved in 500 mL of water, consumed once under fasting conditions, to evaluate acute effects on platelet function (reactivity and blood risk), postprandial glycemia, and total polyphenol concentration at baseline (0 hours), 2 hours, and 6 hours after SPVCE consumption.
Eligibility Criteria
You may qualify if:
- Voluntary participant
- Men and women aged 20-59 years
- Willingness to participate and provide written informend consent
You may not qualify if:
- Documented food allergies, especially ti legumes or beans
- Diagnosed liver, kidney, , autoinmune diseases or severe illnesses such as cancer.
- Diagnosed gastrointestinal diseases including inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease, or any condition causing chronic gastrointestinal symptoms such as malabsorption, persistent diarrhea, or gastrointestinal bleeding
- Use medication known to alter platelet funtion like, antiplatelet agents (aspirin, clopidogrel); Non-steroidal anti-inflamatory drugs (NSAID-Ibuprofen, naproxen); Anticoagulants (Warfarin, heparin, direct oral anticoagulant like rivaroxaban or apixaban); Selective serotonin reuptake inhibitors (SSRIs) and other drugs known to impact platelet aggregation or hemostasis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Talcalead
- Centro de Estudios en Alimentos Procesadoscollaborator
Study Sites (1)
Universidad de Talca
Talca, Maule Region, 3460057, Chile
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Iván Francisco Palomo González
- Organization
- University of Talca
Study Officials
- PRINCIPAL INVESTIGATOR
Ivan F Palomo Gonzalez, PhD. Biomedical Science
University of Talca
- STUDY CHAIR
Eduardo J Fuentes Quinteros, PhD. Science research
University of Talca
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 20, 2025
First Posted
June 29, 2025
Study Start
March 13, 2025
Primary Completion
June 19, 2025
Study Completion
June 19, 2025
Last Updated
April 9, 2026
Results First Posted
April 9, 2026
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared. As stated in the informed consent, participation is strictly confidential; participant names and identifiers are not used. Blood samples are coded and not linked to personal data. Identity and health information will not be disclosed or shared outside the study team.